312 related articles for article (PubMed ID: 19004541)
21. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
22. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
Busse A; Asemissen AM; Nonnenmacher A; Braun F; Ochsenreither S; Stather D; Fusi A; Schmittel A; Miller K; Thiel E; Keilholz U
Eur J Cancer; 2011 Mar; 47(5):690-6. PubMed ID: 21215610
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
26. Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Procopio G
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1689-92. PubMed ID: 22050017
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib in renal cell carcinoma.
Flaherty KT
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):747s-752s. PubMed ID: 17255304
[TBL] [Abstract][Full Text] [Related]
28. Bowel perforation after radiotherapy in a patient receiving sorafenib.
Peters NA; Richel DJ; Verhoeff JJ; Stalpers LJ
J Clin Oncol; 2008 May; 26(14):2405-6. PubMed ID: 18467733
[No Abstract] [Full Text] [Related]
29. Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Takeuchi A; Eto M; Tatsugami K; Yamada H; Oki T; Kiyoshima K; Yoshikai Y; Naito S
J Urol; 2010 Dec; 184(6):2549-56. PubMed ID: 21030044
[TBL] [Abstract][Full Text] [Related]
30. Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson TE
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1193-202. PubMed ID: 17892420
[TBL] [Abstract][Full Text] [Related]
31. Transient perforating folliculitis induced by sorafenib.
Minami-Hori M; Ishida-Yamamoto A; Komatsu S; Iiduka H
J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
[No Abstract] [Full Text] [Related]
32. Sorafenib rechalenge in metastatic renal cell carcinoma.
Porta C; Paglino C; Imarisio I
BJU Int; 2012 Sep; 110(6 Pt B):E235. PubMed ID: 22332769
[No Abstract] [Full Text] [Related]
33. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Rey PM; Villavicencio H
Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
[TBL] [Abstract][Full Text] [Related]
35. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Kats-Ugurlu G; Maass C; van Herpen C; de Waal R; Oosterwijk E; Mulders P; Hulsbergen-van de Kaa C; Leenders W
Histopathology; 2011 Sep; 59(3):562-4. PubMed ID: 22034894
[No Abstract] [Full Text] [Related]
36. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
37. Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
Tai CJ
Acta Oncol; 2009; 48(6):931-2. PubMed ID: 19925379
[No Abstract] [Full Text] [Related]
38. Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Kasibhatla M; Steinberg P; Meyer J; Ernstoff MS; George DJ
Clin Genitourin Cancer; 2007 Mar; 5(4):291-4. PubMed ID: 17553211
[TBL] [Abstract][Full Text] [Related]
39. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
Block MS; Kohli M
Clin Adv Hematol Oncol; 2011 Apr; 9(4):335-8. PubMed ID: 21558995
[No Abstract] [Full Text] [Related]
40. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
